Guided de-escalation of antiplatelet treatment in patients at high atherothrombotic risk presenting with acute coronary syndrome: a post hoc analysis of the TROPICAL-ACS trial
Clinical Snapshot
PICO Framework
| P — Population | ACS patients from TROPICAL-ACS trial stratified by atherothrombotic risk (high ATR: age ≥65, polyvascular disease, or ≥2 risk factors including diabetes, smoking, renal dysfunction; n=990 high ATR, n=1620 low ATR) |
| I — Intervention | Platelet function testing-guided de-escalation from prasugrel to clopidogrel |
| C — Comparator | Standard 12-month prasugrel therapy |
| O — Outcomes | Primary: composite of cardiovascular death, myocardial infarction, stroke, or BARC 2-5 bleeding; Secondary: ischaemic events |
Bottom Line
This post hoc analysis of TROPICAL-ACS found that platelet function testing-guided de-escalation from prasugrel to clopidogrel was safe in both high and low atherothrombotic risk ACS patients, with no significant increase in ischaemic events. However, the study failed to demonstrate significant clinical benefit in either risk group, with wide confidence intervals suggesting insufficient power for definitive conclusions. High-risk patients had higher overall event rates as expected, but the interaction between de-escalation strategy and risk status was not significant. While the safety profile supports the feasibility of PFT-guided de-escalation across risk categories, the lack of clear benefit and methodological limitations of post hoc subgroup analysis limit the strength of recommendations. Clinicians should consider individual patient factors and bleeding risk when contemplating early DAPT de-escalation, particularly in high atherothrombotic risk patients where the risk-benefit balance remains uncertain.
Key Findings
P Value: High ATR: P=0.586; Low ATR: P=0.082; Interaction P=0.394
Effect Size: High ATR: HR 0.90 (0.61-1.32); Low ATR: HR 0.71 (0.48-1.04)
Primary Outcome: Composite of cardiovascular death, MI, stroke, or BARC 2-5 bleeding: High ATR 10.5% vs 11.5% (HR 0.90); Low ATR 5.6% vs 7.7% (HR 0.71)
Nnt Or Sensitivity: No significant benefit demonstrated; NNT cannot be calculated for non-significant results
Confidence Interval: High ATR: 95% CI 0.61-1.32; Low ATR: 95% CI 0.48-1.04
Clinical Application
Requires platelet function testing capability and expertise in DAPT management; may be resource-intensive Relevant to Australian cardiology practice; prasugrel and clopidogrel both PBS-listed; aligns with CSANZ ACS guidelines emphasising individualised antiplatelet therapy ACS patients suitable for dual antiplatelet therapy, particularly those where bleeding risk reduction is prioritised
Abstract
AIMS: Platelet function testing (PFT)-guided de-escalation of dual antiplatelet therapy (DAPT) after acute coronary syndrome (ACS) has been shown to reduce bleeding risk without increasing ischaemic events. Patients with high atherothrombotic risk (ATR) remain a challenging subgroup for such strategies. This study evaluated the safety and efficacy of early PFT-guided DAPT de-escalation according to ATR status. METHODS AND RESULTS: In the TROPICAL-ACS trial, 2610 ACS patients were randomized to standard 12-month prasugrel therapy or PFT-guided DAPT de-escalation. For this post hoc analysis, patients were stratified by ATR. High ATR was defined as age ≥ 65 years, polyvascular disease, or ≥2 risk factors (diabetes, smoking, or renal dysfunction). Hazard ratios (HRs) for clinical endpoints were derived using multistate Cox regression. High-ATR patients (n = 990) had a higher incidence of the primary net clinical benefit endpoint-composite of cardiovascular death, myocardial infarction, stroke, or Bleeding Academic Research Consortium 2-5 bleeding-compared with low-ATR patients (n = 1620) (11.0% vs. 6.7%; HR 1.67, 95% confidence interval 1.28-2.18; P < 0.001). Platelet function testing-guided de-escalation showed no significant interaction by ATR status for the primary endpoint [high ATR: 10.5% vs. 11.5%, HR 0.90 (0.61-1.32), P = 0.586; low ATR: 5.6% vs. 7.7%, HR 0.71 (0.48-1.04), P = 0.082; Pinteraction = 0.394] or ischaemic events [high ATR: 3.7% vs. 4.4%, HR 0.83 (0.44-1.56); low ATR: 1.8% vs. 2.6%, HR 0.68 (0.35-1.34); Pinteraction = 0.666]. CONCLUSION: Early PFT-guided de-escalation from prasugrel to clopidogrel was safe across atherothrombotic risk categories, supporting individualized DAPT optimization in ACS patients with both low and high ischaemic risk.
References
- 1.Farhan, S., Hein, R., Trenk, D., Gross, L., Löw, A., Orban, M., Orban, M., Geisler, T., Naumann, D., Huczek, Z., Koltowski, L., Baylacher, M., Vogel, B., Huber, K., Massberg, S., Sibbing, D., & Rizas, K. D. (2026). Guided de-escalation of antiplatelet treatment in patients at high atherothrombotic risk presenting with acute coronary syndrome: A post hoc analysis of the TROPICAL-ACS trial. European Heart Journal: Acute Cardiovascular Care. https://doi.org/10.1093/ehjacc/zuaf172
Related Research
Bioelectrochemistry (Amsterdam, Netherlands)
From data to diagnosis: A comprehensive review of machine learning-driven wearable sensors in healthcare.
2 Aug 2026
Ultrasound in medicine & biology
A Systematic Review: The Application of Attention Mechanisms in Medical Ultrasound Image Processing
2 Aug 2026
Journal of the American Medical Informatics Association : JAMIA
Explainable machine learning in healthcare: methods, interpretation, and applications for clinical research
2 Aug 2026
This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service